APA (7th ed.) Citation

Vienot, A., Jacquin, M., Rebucci-Peixoto, M., Pureur, D., Ghiringhelli, F., Assenat, E., . . . Borg, C. (2023). Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A randomized non-comparative phase II study (TERTIO – PRODIGE 82). BMC.

Chicago Style (17th ed.) Citation

Vienot, Angélique, et al. Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived from Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Randomized Non-comparative Phase II Study (TERTIO – PRODIGE 82). BMC, 2023.

MLA (9th ed.) Citation

Vienot, Angélique, et al. Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived from Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Randomized Non-comparative Phase II Study (TERTIO – PRODIGE 82). BMC, 2023.